Rhythm Pharmaceuticals, Inc.

This study tests a daily injection called setmelanotide to help people aged 4 and older who gained weight after a brain injury (hypothalamic obesity). The goal is to see if it reduces body weight, hunger, and improves quality of life over 52 weeks. Half of the 143 participants wi…

This phase 2 trial tests setmelanotide (Imcivree), a daily injection, in 18 people aged 6 to 65 with Prader-Willi syndrome who have obesity. The study will check if the drug is safe and helps reduce body weight and hunger over 52 weeks.

This study looks at the long-term safety and effects of a drug called bivamelagon in people with hypothalamic obesity, a condition where the brain's hunger control is damaged. About 25 participants who completed a previous study will take the drug for up to 2 years. Researchers w…

This phase 3 trial is testing a drug called setmelanotide in people with obesity linked to certain gene variants (POMC, PCSK1, LEPR, NCOA1, or SH2B1). About 296 participants, aged 6 to 65, will receive either the drug or a placebo to see if it helps reduce body weight. The study …

This study looks at the long-term safety of setmelanotide (Imcivree) in 30 people aged 2 and older with rare genetic obesity. Participants have already completed a previous setmelanotide study and shown benefit. They will receive daily injections to see if the drug remains safe a…